Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence

References

• World Health Org Adherence to long-term therapies. URL: http://www.who.int/chp/knowledge/publications/adherence_report/en/index.html. Accessed Feb 26, 2007
   Google Scholar
• PartridgeAHAvornJWangPSWinerEPAdherence to therapy with oral antineoplastic agentsJ Natl Cancer Inst200294652656111983753
   PubMed Web of Science ®Google Scholar
• LeeWCBaluSCobdenDJoshiAVPashosCLPrevalence and economic consequences of medication adherence in diabetes: a systematic literature reviewManag Care Interface200619314116898343
   PubMedGoogle Scholar
• Who gets MS? URL: http://www.nationalmssociety.org/about-multiple-sclerosis/who-gets-ms/index.aspx. Accessed May 21, 2009
   Google Scholar
• WeinshenkerBGBassBRiceGPNoseworthyJCarriereWBaskervilleJThe natural history of multiple sclerosis: a geographically based study. 1. Clinical course and disabilityBrain1989112(Pt 1):1331462917275
   PubMed Web of Science ®Google Scholar
• GonsetteREMitoxantrone immunotherapy in multiple sclerosisMult Scler199613293329345411
   PubMedGoogle Scholar
• NatalizumabSPC URL: http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=18447. Accessed Nov 29, 2007
   Google Scholar
• TremlettHLOgerJInterrupted therapy: stopping and switching of the beta-interferons prescribed for MSNeurology20036155155412939437
   PubMed Web of Science ®Google Scholar
• MohrDCGoodkinDELikoskyWGattoNNeilleyLKGriffinCTherapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatmentMult Scler199622222269050360
   PubMedGoogle Scholar
• PortaccioEZipoliVSiracusaGSorbiSAmatoMPLong-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosisEur Neurol20085913113518057899
   PubMed Web of Science ®Google Scholar
• RioJPorcelJTellezNSanchez-BetancourtATintoreMArevaloMJFactors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosisMult Scler20051130630915957512
   PubMed Web of Science ®Google Scholar
• RaoSMLeoGJBernardinLUnverzagtFCognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and predictionNeurology1991416856912027484
   PubMed Web of Science ®Google Scholar
• MohrDCGoodkinDELikoskyWGattoNBaumannKARudickRATreatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosisArch Neurol1997545315339152109
   PubMed Web of Science ®Google Scholar
• ClericoMBarberoPContessaGFerreroCDurelliLAdherence to interferon-beta treatment and results of therapy switchingJ Neurol Sci200725910410817376486
   PubMed Web of Science ®Google Scholar
• FrohmanEPhillipsTKokelKVan PeltJO’LearySGrossSDisease-modifying therapy in multiple sclerosis: strategies for optimizing managementNeurologist2002822723612803682
   PubMed Web of Science ®Google Scholar
• BayasARieckmannPManaging the adverse effects of interferon beta therapy in multiple sclerosisDrug Saf20002214915910672896
   PubMed Web of Science ®Google Scholar
• PRISMS Study Group, University of British Columbia MS/MRI Analysis GroupPRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MSNeurology2001561628163611425926
   PubMed Web of Science ®Google Scholar
• KapposLTraboulseeAConstantinescuCEralinnaJPForrestalFJongenPLong-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MSNeurology20066794495317000959
   PubMed Web of Science ®Google Scholar
• AvonexSPC URL: http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=257. Accessed Nov 29, 2007
   Google Scholar
• BetaferonSPC URL: http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=1809. Accessed Nov 29, 2007
   Google Scholar
• RebifSPC URL: http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=18578. Accessed Nov 29, 2007
   Google Scholar
• EdgarCMBrunetDGFentonPMcBrideEVGreenPLipoatrophy in patients with multiple sclerosis on glatiramer acetateCan J Neurol Sci200431586315038472
   PubMed Web of Science ®Google Scholar
• SoosNShakeryKMrowietzULocalized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosisAm J Clin Dermatol2004535735915554737
   PubMed Web of Science ®Google Scholar
• WaltherEUHohlfeldRMultiple sclerosis: side effects of interferon beta therapy and their managementNeurology1999531622162710563602
   PubMed Web of Science ®Google Scholar
• LesauxJJadbackGHarraghyCEImproving the convenience of home-based interferon beta-1a therapy for multiple sclerosisJ Neurosci Nurs19993117417910846648
   PubMedGoogle Scholar
• CoxDStoneJManaging self-injection difficulties in patients with relapsing-remitting multiple sclerosisJ Neurosci Nurs20063816717116817668
   PubMedGoogle Scholar
• RichterAAntonSEKochPDennettSLThe impact of reducing dose frequency on health outcomesClin Ther2003252307233514512137
   PubMed Web of Science ®Google Scholar
• O’RourkeKEHutchinsonMStopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patternsMult Scler200511465015732266
   PubMed Web of Science ®Google Scholar
• Al-SabbaghABennetRKozmaCDicksonMMeleticheDMedication gaps in disease-modifying therapy for multiple sclerosis are associated with an increased risk of relapse: findings from a national managed care databaseJ Neurol2008255Suppl 2S79
   Google Scholar
• MikolDLopez-BresnahanMTaraskiewiczSChangPRangnowJA randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosisMult Scler20051158559116193898
   PubMed Web of Science ®Google Scholar
• CramerJACuffelBJDivanVAl-SabbaghAGlassmanMPatient satisfaction with an injection device for multiple sclerosis treatmentActa Neurol Scand200611315616216441244
   PubMed Web of Science ®Google Scholar
• RioJNosCBonaventuraIArroyoRGenisDSuredaBCorticosteroids, ibuprofen, and acetaminophen for IFNbeta-1a flu symptoms in MS: a randomized trialNeurology20046352552815304586
   PubMed Web of Science ®Google Scholar
• DenisLNameyMCostelloKFrenetteJGagnonNHarrisCLong-term treatment optimization in individuals with multiple sclerosis using disease-modifying therapies: a nursing approachJ Neurosci Nurs200436102214998102
   PubMedGoogle Scholar
• MohrDCGoodkinDEMasuokaLDickLPRussoDEckhardtJTreatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosisMult Scler1999519219710408720
   PubMed Web of Science ®Google Scholar
• GlanzBHollandCGauthierSAmunwaELiptakZHoutchensMCognitive dysfunction in patients with clinically isolated syndromes or newly diagnosed multiple sclerosisMult Scler2007131004101017623735
   PubMed Web of Science ®Google Scholar
• GiovannoniGBarbarashOCasset-SemanazFKingJMetzLPardoGSafety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a phase IIIb study in patients with relapsing multiple sclerosis: 96-week resultsMult Scler20091521922818755819
   PubMed Web of Science ®Google Scholar
• PhillipsJTRiceGFrohmanEVande GaerLScottTHaasJA multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosisClin Ther20042651152115189748
   PubMed Web of Science ®Google Scholar
• BellarySBarnettAHInhaled insulin (Exubera): Combining efficacy and convenienceDiab Vasc Dis Res2006317918517160913
   PubMedGoogle Scholar
• FallowfieldLAtkinsLCattSCoxACoxonCLangridgeCPatients’ preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancerAnn Oncol20061720521016239231
   PubMed Web of Science ®Google Scholar
• LiuGFranssenEFitchMIWarnerEPatient preferences for oral versus intravenous palliative chemotherapyJ Clin Oncol1997151101158996131
   PubMed Web of Science ®Google Scholar
• AtkinsonMJSinhaAHassSLColmanSSKumarRNBrodMValidation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic diseaseHealth Qual Life Outcomes2004212122414987333
   PubMedGoogle Scholar
• ReginsterJYRabendaVNeuprezAAdherence, patient preference and dosing frequency: understanding the relationshipBone200638S2S616520104
   PubMed Web of Science ®Google Scholar
• ClotetBCarmenaJPulidoFLuqueIRodriguez-AlcantaraFAdherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on antiretroviral-experienced patientsHIV Clin Trials20045333915002085
   PubMed Web of Science ®Google Scholar
• SleightPPouleurHZannadFBenefits, challenges, and registerability of the polypillEur Heart J2006271651165616603580
   PubMed Web of Science ®Google Scholar
• RauJLDeterminants of patient adherence to an aerosol regimenRespir Care2005501346135616185370
   PubMedGoogle Scholar
• KrukMESchwalbeNThe relation between intermittent dosing and adherence: preliminary insightsClin Ther2006281989199517296456
   PubMed Web of Science ®Google Scholar
• YangJSXuLYXiaoBGHedlundGLinkHLaquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis ratsJ Neuroimmunol20041563915465591
   PubMed Web of Science ®Google Scholar
• KapposLMillerDMacManusDGGoldRHavrdovaELimmrothVBG00012, a novel oral fumarate, is effective in patients with relapsing–remitting multiple sclerosisMult Scler200612Suppl 1P325
   Google Scholar
• KapposLAntelJComiGMontalbanXO’ConnorPPolmanCHOral fingolimod (FTY720) for relapsing multiple sclerosisN Engl J Med20063551124114016971719
   PubMed Web of Science ®Google Scholar
• First Phase III results for FTY720, a novel oral therapy for MS, show superior efficacy compared to interferon beta-1a. URL: http://www.pharma.us.novartis.com/newsroom/press-release.jsp?PRID=2179&usertrack.filter_applied=true&NovaId=1178761806479528335. Accessed Feb 10, 2009
   Google Scholar
• ZeydaMPoglitschMGeyereggerRSmolenJSZlabingerGJHorlWHDisruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formationArthritis Rheum2005522730273916142756
   PubMed Web of Science ®Google Scholar
• BeutlerESipeJCRomineJSKoziolJAMcMillanRZyroffJThe treatment of chronic progressive multiple sclerosis with cladribineProc Natl Acad Sci U S A199693171617208643695
   PubMed Web of Science ®Google Scholar
• Soelberg-SorensenPComiGCookSGiovannoniGRammohanKRieckmannPHaematological profiles in patients treated with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS): results from the CLARITY study, a 96 week, phase III, double-blind, placebo-controlled trialJ Neurol2009256S127S128
   Web of Science ®Google Scholar
• ChitnisTThe role of CD4 T cells in the pathogenesis of multiple sclerosisInt Rev Neurobiol200779437217531837
   PubMed Web of Science ®Google Scholar
• BabbeHRoersAWaismanALassmannHGoebelsNHohlfeldRClonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reactionJ Exp Med200019239340410934227
   PubMed Web of Science ®Google Scholar
• RiceGPFilippiMComiGCladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study GroupNeurology2000541145115510720289
   PubMed Web of Science ®Google Scholar
• GriebPKamienowskiJJaniszMKuœnierczykPKawiakJHoserGHematological effects of intermittent 2-hour infusions of cladribine in multiple sclerosis patients: a comparison of 2 dosage patternsInt J Hematol20017442142711794698
   PubMed Web of Science ®Google Scholar
• Soelberg-SorensenPComiGCookSGiovannoniGRammohanKRieckmannPEffects of cladribine tablets on haematological profiles in patients with relapsing-remitting multiple sclerosis (RRMS) in the 96 week, phase III, double blind, placebo-controlled CLARITY studyMult Scler200915S137
   Google Scholar
• RomineJSSipeJCKoziolJAZyroffJBeutlerEA double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosisProc Assoc Am Physicians199911135449893155
   PubMedGoogle Scholar
• Merck Serono’s Oral Investigational Treatment Cladribine Tablets for Multiple Sclerosis Significantly Reduced Relapse Rate in Two-Year Phase III Pivotal Trial. URL: http://www.merckserono.com/corp.merckserono/en/images/20090123_en_tcm112_34916.pdf. Accessed Feb 10, 2009
   Google Scholar
• GiovannoniGComiGCookSRammohanKRieckmannPSorensenPClinical outcomes with cladribine tablets in the 96-week, phase III, double-blind, placebo-controlled CLARITY study in patients with relapsing-remitting multiple sclerosisMult Scler200915S136S137
   Web of Science ®Google Scholar
• VermerschPComiGCookSGiovannoniGRammohanKRieckmannPEarly onset of effect of treatment with cladribine tablets for relapsing-remitting multiple sclerosis in the 96-week, phase III, double-blind, placebo-controlled CLARITY studyMult Scler200915S249
   Google Scholar